Pitcairn Co. Purchases 4,509 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pitcairn Co. grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 117.0% in the first quarter, HoldingsChannel.com reports. The fund owned 8,364 shares of the medical equipment provider’s stock after acquiring an additional 4,509 shares during the period. Pitcairn Co.’s holdings in Lantheus were worth $521,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Shaker Investments LLC OH increased its stake in shares of Lantheus by 0.7% in the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after acquiring an additional 182 shares during the last quarter. NBC Securities Inc. increased its stake in shares of Lantheus by 28.4% in the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 191 shares during the last quarter. Retirement Systems of Alabama increased its stake in shares of Lantheus by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock valued at $5,353,000 after acquiring an additional 226 shares during the last quarter. FinTrust Capital Advisors LLC increased its stake in shares of Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 232 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in shares of Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

LNTH has been the subject of a number of recent analyst reports. B. Riley upped their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. JMP Securities boosted their price objective on Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, July 10th. Truist Financial boosted their price objective on Lantheus from $96.00 to $141.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Finally, SVB Leerink boosted their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $120.57.

Lantheus Trading Down 0.6 %

NASDAQ:LNTH opened at $112.95 on Friday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The business has a 50 day moving average price of $88.47 and a two-hundred day moving average price of $70.89. The company has a market cap of $7.83 billion, a P/E ratio of 17.24 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the sale, the insider now owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders sold a total of 44,799 shares of company stock valued at $3,769,262 in the last quarter. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.